SCHEMBL8167297

SCHEMBL8167297

O=C1NCc2cc(-c3ccccc3)ccc21

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.75
NTRK2 Q16620 2/20 0.75
DYRK1B Q9Y463 2/20 0.75
TYRO3 Q06418 1/20 0.75
PARP10 Q53GL7 5/20 0.71
PARP11 Q9NR21 5/20 0.71
TDP2 O95551 3/20 0.63
GSK3B P49841 3/20 0.60
NTRK1 P04629 2/20 0.60
FLT3 P36888 2/20 0.60
DAPK3 O43293 1/20 0.60
PIM1 P11309 1/20 0.60
ROCK1 Q13464 1/20 0.60
GRM5 P41594 1/20 0.59
CA12 O43570 1/20 0.58
CA9 Q16790 1/20 0.58
PRF1 P14222 3/20 0.55
JAK2 O60674 1/20 0.54
MET P08581 1/20 0.54
FGFR1 P11362 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8723086 0.86 CLK4 (1.00) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL13680532 0.83 CLK4 (0.78) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL10243599 0.83 PARP10 (0.74) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL8155722 0.83 PARP11 (1.00) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL2014718 0.81 PRF1 (0.61) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL2017969 0.81 PRF1 (0.64) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL25292799 0.80 PARP11 (0.82) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL14847348 0.80 CLK4 (0.51) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL8163189 0.79 GSK3B (0.75) CLK4NTRK2DYRK1BTYRO3PARP10
SCHEMBL18010841 0.77 TDP2 (1.00) TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
WO-2008151184-A1 BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME VANDERBILT UNIVERSITY (US) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CLK4 3903/4885NTRK2 4356/4885DYRK1B 4797/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CLK4 3903/4885NTRK2 4356/4885DYRK1B 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.